You are here
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
SBC: Flow Pharma, Inc. Topic: CBD18A002
Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
SBC: POLARONYX INC Topic: DHP15B002
Based on our success in developing the world first commercial high energy femtosecond fiber laser system and our leading proprietary technology development in ultrashort pulsed fiber laser material processing, PolarOnyx proposes, for the first time, a compact high energy fiber laser based smart wound healing tool to meet with the requirement of this DHP solicitation. It includes a high energy fs f ...STTR Phase I 2016 Department of DefenseDefense Health Agency